Clinical trials: Tislelizumab
Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients .
- Conditions
- Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC, PD-1antibody
- Trial name
- NCT05912816
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Extensive Stage Lung Small Cell Cancer
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
This is an open-label umbrella study conducted in first treatment ES-SCLC patients, employing a novel umbrella trial design (biomarker-integrated multi-arm trial with a shared ICI+chemotherapy control arm).
- Trial name
- NCT07172412
- Testing
- Selinexor, Anlotinib, DLL3 CAR-NK cells
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Digestive System Neoplasms
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
This study is a prospective, non-randomized, dual-cohort Phase II clinical trial designed to explore the efficacy and safety of radiotherapy combined with intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis…
- Trial name
- NCT07196540
- Testing
- Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Lymph Node Metastasis, Neurovascular Invasion
Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）
The purpose of this prospective, observational study is to investigate whether adjuvant chemoradiotherapy combined with immunotherapy for high-risk recurrence populations after extrahepatic cholangiocarcinoma resection can…
- Conditions
- Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection
- Trial name
- AICRC (NCT06997913)
- Testing
- Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk resectable Extrahepatic Cholangiocarcinoma（AICRC）
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hengchao Yu
Fumarate Hydratase Deficient Renal Cell Carcinoma
A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
FHRCC is a rare kind of renal cell carcinoma with a morbidity of 1/2000000 per year.Although several combination therapies demonstrated possible efficacy in this population. No standard treatment has been approved.
- Trial name
- NCT05877820
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic…
- Trial name
- NCT06416410
- Testing
- JAB-21822, Tislelizumab, JAB-3312
- Where
- 37 sites in China
- Volunteers
- 392 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Untreated Advanced Non-small Cell Lung Cancer
Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer
This is a single-arm, single-centre phase II study to evaluate the efficacy (PFS, ORR, DCR) and safety of recombinant human adenovirus type 5 in combination with tirelizumab and platinum-containing dual-agent chemotherapy in…
- Trial name
- NCT06136910
- Testing
- Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Rectal Cancer Patients
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
To evaluate the safety and preliminary efficacy of preoperative chemotherapy and PD-1 inhibitor Tislelizumab for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the…
- Trial name
- NCT06647680
- Testing
- Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Hodgkin Lymphoma
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
This trial investigates the efficacy and safety of the drug tislelizumab in combination with chemotherapy as a treatment for patients with R/R HL.
- Trial name
- HOVON164HL (NCT05502250)
- Testing
- gemcitabine, cisplatin and tislelizumab
- Where
- 15 sites in Belgium, Denmark and 1 more
- Volunteers
- 75 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Esophageal Squamous Cell Carcinoma (ESCC)
Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma
Patients with esophageal cancer still face a high risk of recurrence after receiving neoadjuvant chemoradiotherapy (nCRT) combined with radical surgery, especially for those who do not achieve pathological complete response…
- Trial name
- NCT07067450
- Testing
- Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab), Observation
- Volunteers
- 98 people
- Sponsor
- Sichuan University
Limited Stage Small Cell Lung Cancer
Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of…
- Trial name
- NCT04952597
- Testing
- Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 126 people
- Sponsor
- BeiGene
Rectal Neoplasms
Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer
Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed.
- Trial name
- NECI (NCT05420584)
- Testing
- Arterial chemoembolization, Tislelizumab Injection, XELOX
- Where
- China
- Volunteers
- 83 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Advanced Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the…
- Trial name
- NCT04799548
- Testing
- Transcatheter Arterial Chemoembolization, Tislelizumab
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the…
- Trial name
- DETECT (NCT05578287)
- Testing
- Anti-HER2 ADC
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Large B-cell Lymphoma
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
This is a phase ll study of participants with large B Cell lymphoma previously treated with anti-CD19 Chimeric antigen receptor (CAR-T) therapy.
- Trial name
- ZeTA (NCT06167785)
- Testing
- Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Resectable Non-Small-Cell Lung Cancer
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
- Trial name
- NCT06607926
- Testing
- Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor…
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT07132008
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 94 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
ESCC, Total Neoadjuvant Treatment
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
Effective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer.
- Conditions
- ESCC, Total Neoadjuvant Treatment, Pathological Complete Response
- Trial name
- NICE-ESCC (NCT06764355)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Rectal Cancer
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
The goal of this clinical trial is to evaluating the efficacy and safety of radiotherapy combined with Tislelizumab, Liposomal Irinotecan, and Capecitabine in patients with locally advanced mid-lower rectal cancer with pMMR..
- Trial name
- NCT07104604
- Testing
- Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Affiliated Cancer Hospital of Shantou University Medical College
Non-Small Cell Squamous Lung Cancer, Brain Metastases
Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain metastases who had not previously received systemic…
- Trial name
- NCT05207904
- Testing
- Tislelizumab, paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University